Skip to main content
SpringerLink
Log in

Systemic T-Cell Immunotherapy for Brain Tumors

  • Chapter
Brain Tumor Immunotherapy

Abstract

Malignant brain tumors (BT) are difficult to treat effectively using current surgery, radiotherapy, and chemotherapy approaches (1–3). The authors have explored the use of T-cell immunotherapy (IT) to treat BTs in an extensive series of preclinical studies and, more recently, in clinical trials. Theoretically, the existence of the blood-brain barrier (BBB) and the lack of a lymphatic drainage system in the brain would impede the ability to elicit an afferent immune response (IR) Indeed, early studies using transplantation of allogeneic tissues established the concept of “immune privilege” for the brain (4,5). However, there is ample clinical (6,7), and experimental (8) evidence that the brain is permissive for T-cell-mediated efferent IRs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Hildebrand, J., Dewitte, O., Dietrich, P. Y., and de Tribolet, N. (1997) Management of malignant brain tumors. Eur. Neurol. 38, 238–253.

    Article  PubMed  CAS  Google Scholar 

  2. Miyamoto, C. (1998) Principles of treatment of malignant gliomas in adults: an overview. J. Neurovirol. 4, 204–216.

    Article  PubMed  Google Scholar 

  3. Black, P. (1998) Management of malignant glioma: role of surgery in relation to multimodality therapy. J. Neurovirol. 4, 227–236.

    Article  PubMed  CAS  Google Scholar 

  4. Medawar, P. W. (1948) Immunity to homologous grafted skin. III. The fate of skin homo-grafts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br. J. Exp. Pathol. 29, 58–69.

    PubMed  CAS  PubMed Central  Google Scholar 

  5. Head, J. R. and Griffin, W. S. T. (1985) Functional capacity of solid tissue implants in the brain: evidence for immunological privilege. Proc. R. Soc. 224, 375–387.

    Article  CAS  Google Scholar 

  6. Raine, C. S. (1984) Biology of disease. The analysis of autoimmune demyelination: its impact upon multiple sclerosis. Lab. Invest. 50, 608–635.

    PubMed  CAS  Google Scholar 

  7. Hafler, D. A. and Weiner, H. L. (1987) T cells in multiple sclerosis and inflammatory central nervous system disease. Immunol. Rev. 100, 307–332.

    Article  PubMed  CAS  Google Scholar 

  8. Oldstone, M. B. A. and Southern, P. J. (1993) Trafficking of activated cytotoxic T lymphocytes into the central nervous system: use of a transgenic model. J. Neuroimmunol. 46, 25–32.

    Article  PubMed  CAS  Google Scholar 

  9. Jacobs, S. K., Wilson, D. J., Kornblith, P. L., and Grimm, E. A. (1986) Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. J. Neurosurg. 64, 743–749.

    Article  PubMed  CAS  Google Scholar 

  10. Yoshida, S., Tanaka, R., Takai, N., and Ono, K. (1988) Local administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with malignant brain tumors. Cancer Res. 48, 5011–5016.

    PubMed  CAS  Google Scholar 

  11. Merchant, R. E., Merchant, L. H., Cook, S. H. S., McVicar, D. W., and Young, H. F. (1988) Intralesional infusion of lymphokine-activated killer cells and recombinant interleukin-2 for the treatment of patients with malignant brain tumor. Neurosurgery 23, 725–732.

    Article  PubMed  CAS  Google Scholar 

  12. Barba, D., Saris, S. C., Holder, C., Rosenberg, S. A., and Oldfield, E. H. (1989) Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J. Neurosurg. 70, 175–182.

    Article  PubMed  CAS  Google Scholar 

  13. Boiardi, A., Silvani, A., Ruffini, P. A., Rivoltini, L., Parmiani, G., Broggi, G., and Salmaggi, A. (1994) Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients. Cancer Immunol. Immunother. 39, 193–197.

    Article  PubMed  CAS  Google Scholar 

  14. Kruse, C. A., Schiltz, P. M., Bellgrau, D., Kong, Q., and Kleinschmidt-De Masters, B. K. (1994) Intracranial administrations of single of multiple source allogeneic cytotoxic T lymphocytes: chronic therapy for primary brain tumors. J. Neuro-oncol. 19, 161–168.

    Article  CAS  Google Scholar 

  15. Hayes, R. L., Koslow, M., Hiesiger, E. M., Hymes, K. B., Hochster, H. S., Moore, E. J., et al. (1995) Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 76, 840–852.

    Article  PubMed  CAS  Google Scholar 

  16. Sankhla, S. K., Nadkarni, J. S., and Bhagwati, S. N. (1996) Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors. J. Neuro-oncol. 27, 133–140.

    CAS  Google Scholar 

  17. Kruse, C. A., Cepeda, L., Owens, B., Johnson, S. D., Stears, J., and Lillehei, K. O. (1997) Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol. Immunother. 45, 77–87.

    Article  PubMed  CAS  Google Scholar 

  18. Mitchell, M. S. (1989) Relapse in the central nervous system in melanoma patients successfully treated with biomodulators. J. Clin. Oncol. 7, 1701–1709.

    PubMed  CAS  Google Scholar 

  19. Saris, S. C., Rosenberg, S. A., and Friedman, R. B. (1988) Penetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrier. J. Neurosurg. 69, 29–34.

    Article  PubMed  CAS  Google Scholar 

  20. Saris, S. C., Patronas, N. J., Rosenberg, S. A., Alexander, J. T., Frank, J., Schwartzentruber, D. J., et al. (1989) The effect of intravenous interleukin-2 on brain water content. J. Neurosurg. 71, 169–174.

    Article  PubMed  CAS  Google Scholar 

  21. Brooks, W. H., Netsky, M. G., Normansell, D. E., and Horwitz, D. A. (1972) Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor. J. Exp. Med. 136, 1631–1647.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  22. Castelli, M. G., Chiabrando, C., Fanelli, R., Martelli, I., Butti, G., Gaetani, P., and Panletti, P. (1989) Prostaglandin and thromboxane systnesis by human intracranial tumors. Cancer Res. 49, 1505–1508.

    PubMed  CAS  Google Scholar 

  23. Maxwell, M., Galanpoulos, T., Neville-Golden, J., and Antoniades, H. N. (1992) Effect of the expression of transforming growth factor-I32 in primary human glioblastomas on immunosuppression and loss of immune surveillance. J. Neurosurg. 76, 799–804.

    Article  PubMed  CAS  Google Scholar 

  24. Nitta, T., Hishii, M., and Okumura, K. (1994) Selective expression of interleukin-10 gene within glioblastoma multiforme. Brain Res. 49, 122–128.

    Article  Google Scholar 

  25. Huettner, C., Paulus, W., and Roggendorf, W. (1995) Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas. Am. J. Pathol. 146, 317–322.

    PubMed  CAS  PubMed Central  Google Scholar 

  26. Fakhrai, H., Dorigo, O., Shawler, D. L., Lin, H., Mercola, D., Black, K. L., Royston, I., and Sobol, R. E. (1996) Eradication of established intracranial rat gliomas by transforming growth factor-(32 antisense gene therapy. Proc. Natl. Acad. Sci. USA 93, 2909–2914.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  27. Bjorkman, P. J., Saper, M. A., Samraoui, B., Bennett, W. S., Strominger, J. L., and Wiley, D. C. (1987) Structure of the human class I histocompatibility antigen, HLA-A2. Nature 329, 506–512.

    Article  PubMed  CAS  Google Scholar 

  28. Madden, D. R., Gorga, J. C., Strominger, J. L., and Wiley, D. C. (1991) The structure of HLAB27 reveals nonamer self-peptides bound in an extended conformation. Nature 353, 321–325.

    Article  PubMed  CAS  Google Scholar 

  29. Prehn, R. T. and Main, J. M. (1957) Immunity to methylcholanthrene-induced sarcomas. J. Natl. Cancer Inst. 18, 769–778.

    PubMed  CAS  Google Scholar 

  30. Hellstrom, K. E., Hellstrom, I., and Brown, J. P. (1978) Unique and common tumor-specific transplantation antigens of chemically induced mouse sarcomas. Int. J. Cancer 21, 317–322.

    Article  PubMed  CAS  Google Scholar 

  31. Carbone, G., Colombo, M. P., Sensi, M. L., Cernuschi, A., and Parmiani, G. (1983) In vitro detection of cell-mediated immunity to individual tumor-specific antigens of chemically induced BALB/c fibrosarcomas. Int. J. Cancer 31, 483–489.

    Article  PubMed  CAS  Google Scholar 

  32. Urban, J. L. and Schreiber, H. (1992) Tumor antigens. Ann. Rev. Immunol. 10, 617–644.

    Article  CAS  Google Scholar 

  33. Gjertsen, M. K., Bakka, A., Brevik, J., Saeterdal, I., Gedde-Dahl, T., Stokke, K. T., et al. (1996) Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study. Int. J. Cancer 65, 450–453.

    Article  PubMed  CAS  Google Scholar 

  34. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., et al. (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med. 4, 321–327.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  35. Shu, S., Chou, T., and Rosenberg, S. A. (1987) Generation from tumor-bearing mice of lymphocytes with in vitro therapeutic efficacy. J. Immunol. 139, 295–304.

    PubMed  CAS  Google Scholar 

  36. Shu, S., Chou, T., and Rosenberg, S. A. (1987) In vitro differentiation of T-cells capable of mediating the regression of established syngeneic tumors in mice. Cancer Res. 47, 1354–1360.

    PubMed  CAS  Google Scholar 

  37. Chou, T., Chang, A. E., and Shu, S. (1988) Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization: culture requirements and characterization of immunologic specificity. J. Immunol. 140, 2453–2461.

    PubMed  CAS  Google Scholar 

  38. Yoshizawa, H., Chang, A. E., and Shu, S. (1991) Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J. Immunol. 147, 729–737.

    PubMed  CAS  Google Scholar 

  39. Shu, S., Krinock, R. A., Matsumura, T., Sussman, J. J., Fox, B. A., Chang, A. E., and Terman, D. S. (1994) Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells. J. Immunol. 152, 1277–1288.

    PubMed  CAS  Google Scholar 

  40. Marrack, P. and Kappler, J. (1990) The staphylococcal enterotoxins and their relatives. Science 248, 705–711.

    Article  PubMed  CAS  Google Scholar 

  41. Wahl, W. L., Sussman, J. J., Shu, S., and Chang, A. E. (1994) Adoptive immunotherapy of murine intracerebral tumors with anti-CD3/interleukin-2-activated tumor-draining lymph node cells. J. Immunother. 15, 242–250.

    Article  CAS  Google Scholar 

  42. Sussman, J. J., Wahl, W. L., Chang, A. E., and Shu, S. (1995) Unique characteristics associated with systemic adoptive immunotherapy of experimental intracerebral tumors. J. Immunother. 18, 35–44.

    Article  CAS  Google Scholar 

  43. Inoue, M., Plautz, G. E., and Shu, S. (1996) Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells. Cancer Res. 56, 4702–4708.

    PubMed  CAS  Google Scholar 

  44. Plautz, G. E., Touhalisky, J. E., and Shu, S. (1997) Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells. Cell. Immunol. 178, 101–107.

    Article  PubMed  CAS  Google Scholar 

  45. Plautz, G. E., Inoue, M., and Shu, S. (1996) Defining the synergistic effects of irradiation and T-cell immunotherapy for murine intracranial tumors. Cell. Immunol. 171, 277–284.

    PubMed  CAS  Google Scholar 

  46. Bevilacqua, M. P. and Nelson, R. M. (1993) Selectins. J. Clin. Invest. 91, 379–387.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  47. Butcher, E. C. and Picker, L. J. (1996) Lymphocyte homing and homeostasis. Science 272, 60–66.

    Article  PubMed  CAS  Google Scholar 

  48. Mobley, J. L., Rigby, S. M., and Dailey, M. O. (1994) Regulation of adhesion molecule expression by CD8 T cells in vivo. J. Immunol. 153, 5443–5452.

    PubMed  CAS  Google Scholar 

  49. McHeyzer-Williams, M. G. and Davis, M. M. (1995) Antigen-specific development of primary and memory T cells in vivo. Science 268, 106–111.

    Article  PubMed  CAS  Google Scholar 

  50. Kagamu, H., Touhalisky, J. E., Plautz, G. E., Krauss, J. C., and Shu, S. (1996) Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes. Cancer Res. 56, 4338–4342.

    PubMed  CAS  Google Scholar 

  51. Kagamu, H. and Shu, S. (1998) Purification of L-selectinl°W cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes. J. Immunol. 160, 3444–3452.

    PubMed  CAS  Google Scholar 

  52. Plautz, G. E., Barnett, G. H., Miller, D. W., Cohen, B. H., Prayson, R. A., Krauss, J. C., et al. (1998) Systemic T cell adoptive immunotherapy of malignant gliomas. J. Neurosurg. 88, 42–51.

    Article  Google Scholar 

  53. Chachoua, A., Oratz, R., Liebes, L., Alter, R. S., Felice, A., Peace, D., Vilcek, J., and Blum R. H. (1994) Phase lb trial of granulocyte-macrophage colony-stimulating factor combined with murine monoclonal antibody R24 in patients with metastatic melanoma. J. Immunother. 16, 132–141.

    Google Scholar 

  54. Arca, M. J., Krauss, J. C., Aruga, A., Cameron, M. J., Shu, S., and Chang, A. E. (1996) Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor. Cancer Gene Ther. 3, 39–47.

    Google Scholar 

  55. Disis, M. L., Bernhard, H., Shiota, F. M., Hand, S. L., Gralow, J. R., Huseby, E. S., Gillis, S., and Cheever, M. A. (1996) Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 88, 202–210.

    PubMed  CAS  Google Scholar 

  56. Kwak, L. W., Young, H. A., Pennington, R. W., and Weeks, S. D. (1996) Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/ macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc. Natl. Acad. Sci. USA 93, 10,972–10, 977.

    Google Scholar 

  57. Jager, E., Ringhoffer, M., Dienes, H. P., Arand, M., Karbach, J., Jager, D., et al. (1996) Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int. J. Cancer 67, 54–62.

    Article  PubMed  CAS  Google Scholar 

  58. Chang, A. E., Aruga, A., Cameron, M. J., Sondak, V. K., Normolle, D. P., Fox, B. A., and Shu, S. (1997) Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J. Clin. Oncol. 15, 796–807.

    PubMed  CAS  Google Scholar 

  59. Brooks, W. H., Caldwell, H. D., and Morata, R. H. (1974) Immune responses in patients with gliomas. Surg. Neurol. 2, 419–423.

    PubMed  CAS  Google Scholar 

  60. Mahaley, M. S. J., Brooks, W. H., Roszman, T. L., Bigner, D. D., Dudka, L., and Richardson S. (1977) Immunobiology of primary intracranial tumors. Part 1: Studies of the cellular and humoral general immune competence of brain-tumor patients. J. Neurosurg. 46, 467–476.

    Google Scholar 

  61. Roszman, T. L. and Brooks, W. H. (1980) Immunobiology of primary intracranial tumors. III. Demonstration of a qualitative lymphocyte abnormality in patients with primary brain tumors. Clin. Exp. Immunol. 39, 395–402.

    PubMed  CAS  PubMed Central  Google Scholar 

  62. Brem, H., Piantadosi, S., Burger, P. C., Walker, M., Selker, R., Vick, N. A., et al. (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345, 1008–1012.

    Article  PubMed  CAS  Google Scholar 

  63. Sampson, J. H. and Bigner, D. D. (1998) Experimental tumors and the evaluation of neuro-carcinogens, in Russell and Robinstein’s Pathology of Tumors of the Nervous System, 6th ed. ( Bigner, D. D., McLendon, R. E., and Bruner, J. M., eds.) Edward Arnold, London, pp. 167–230.

    Google Scholar 

  64. Beutler, A. S., Banck, M. S., Wedekind, D., and Hedrich, H. J. (1999) Tumor gene therapy made easy: allogenic major histocompatibility complex in the C6 rat glioma model. Human Gene Ther. 10, 95–101.

    Article  CAS  Google Scholar 

  65. Bigner, D. D., Pitts, O. M., and Wikstrand, C. J. (1981) Induction of lethal experimental allergic encephalomyelitis in non-human primates and guinea pigs with human glioblastoma multiforme tissue. J. Neurosurg. 55, 32–42.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Gregory E. Plautz MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Suyu Shu PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. School of Medicine, University of California at Los Angeles, CA, USA

    Linda M. Liau MD, PhD , Donald P. Becker MD  & Timothy F. Cloughesy MD ,  & 

  2. Department of Pathology and Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, NC, USA

    Darell D. Bigner MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Science+Business Media New York

About this chapter

Cite this chapter

Plautz, G.E., Shu, S. (2001). Systemic T-Cell Immunotherapy for Brain Tumors. In: Liau, L.M., Becker, D.P., Cloughesy, T.F., Bigner, D.D. (eds) Brain Tumor Immunotherapy. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-035-3_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-035-3_6

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-110-3

  • Online ISBN: 978-1-59259-035-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation